Investigation of the stability profile of therapeutic α-MSH analogue: Insights from liquid chromatography-high resolution mass spectrometry analysis of afamelanotide.
This study investigated the chemical and physical stability of afamelanotide (melanotan-1), a synthetic 13-amino acid peptidomimetic of α-melanocyte stimulating hormone (α-MSH) approved as an orphan drug for erythropoietic protoporphyria. Researchers subjected the compound to a range of stress conditions — acidic, basic, neutral, oxidative, UV light exposure, and elevated temperature (60°C) — following International Council for Harmonisation (ICH) guidelines Q1A(R2) and Q5C. Using gradient reversed-phase HPLC coupled with ultra-high-performance liquid chromatography–high resolution tandem mass spectrometry (UHPLC-HRMS/MS), the team identified and structurally characterized 14 distinct degradation products. Collision-induced dissociation fragmentation patterns enabled detailed elucidation of each product's structure. Key degradation pathways identified included truncation, methylation, deacetylation, and oxidation. The analytical method was validated per ICH Q2(R1) guidelines. This work is purely analytical and pharmaceutical in nature — it does not involve human subjects, animals, or cell-based experiments. Its primary value lies in establishing a comprehensive stability profile of afamelanotide to inform rational drug formulation design. No clinical outcomes, efficacy, or safety data in biological systems were assessed.
Why this grade: This is a purely analytical/pharmaceutical chemistry study conducted entirely in vitro under controlled stress conditions, with no human subjects, animal models, or cell-based biological systems involved.
Afamelanotide, also known as melanotan-1, is a synthetic 13-amino acid peptidomimetic of α-melanocyte stimulating hormone (α-MSH), and is a critical peptide orphan drug used for the management of erythropoietic protoporphyria. It contains norleucine and D-phenylalanine at positions 4 and 7, in place of methionine and L-phenylalanine, respectively as found in endogenous peptide. Therapeutic peptide stability profiling is crucial in drug development because chemical and physical degradation during storage alters structural properties, potentially reducing efficacy and compromising safety by preventing target engagement. Stability testing for synthetic peptides is performed by following the International Council for Harmonisation (ICH) guidelines Q1A(R2) and Q5C. The current work endeavours to explore afamelanotide's degradation pathways under various chemical and physical stress conditions: acidic, basic, neutral, and oxidative stress, UV light exposure, and increased temperature at 60⁰C. The study demonstrated that afamelanotide undergoes degradation under all applied stress conditions with the generation of fourteen different degradation products (DPs) which were separated by gradient reversed-phase HPLC on a Zorbax SB C18 column (300 Å, 4.6*150 mm, 3.5 µm) and the method was validated according to the ICH Q2(R1) guideline. To enable comprehensive characterization, the analysis was coupled with ultra-high-performance liquid chromatography-high resolution tandem mass spectrometry (UHPLC-HRMS/MS), where collision-induced dissociation yielded abundant and accurate fragmentation patterns, enabling the detailed structural elucidation of the products. While this work has identified several degradation pathways such as truncation, methylation, deacetylation, and oxidation, it also establishes complete stability profile of α-MSH analogue, thus offering key insights for the rational design of robust drug formulations.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.